Point-of-care testing

Point-of-care testing (POCT) refers to medical diagnostic tests performed at or near the site of patient care, delivering results in minutes rather than hours or days. Unlike traditional lab testing, POCT happens at the bedside, in a clinic, at a pharmacy, or even at home, using portable devices that provide immediate clinical data to guide treatment decisions.

What Is Point-of-Care Testing? — 2026 Definition

Point-of-care testing is the practice of conducting diagnostic tests outside a central laboratory, using compact analyzers or single-use test kits that produce results within 15 minutes or less. According to the World Health Organization (WHO, 2025), POCT devices must meet ASSURED criteria—Affordable, Sensitive, Specific, User-friendly, Rapid, Equipment-free, and Delivered to those who need them. Common POCT examples include blood glucose monitors from Abbott and Roche, rapid strep tests from QuidelOrtho, and COVID-19 antigen tests from Abbott’s BinaxNOW. The global POCT market was valued at $52.3 billion in 2025, according to Grand View Research, driven by decentralized healthcare trends.

Feature	Traditional Lab Testing	Point-of-Care Testing
Turnaround time	1–72 hours	5–15 minutes
Location	Centralized lab facility	Bedside, clinic, pharmacy, home
Operator	Certified lab technician	Nurse, pharmacist, patient
Sample type	Venous blood, urine, tissue	Capillary blood, saliva, nasal swab
Regulatory oversight	CLIA high-complexity	CLIA waived (most devices)
Cost per test	$5–$50	$15–$100

How Point-of-Care Testing Works in 2026

Modern POCT relies on biosensor technology, lateral flow assays, and microfluidics to detect biomarkers in small sample volumes. According to the U.S. Centers for Disease Control and Prevention (CDC, 2025), over 200,000 CLIA-waived POCT devices are now registered in the United States, representing a 34% increase since 2022. The Food and Drug Administration (FDA) cleared 18 new POCT devices in 2025 alone, including the Roche cobas liat for respiratory panels and the Abbott i-STAT Alinity for cardiac troponin. These devices use Bluetooth and cellular connectivity to transmit results directly to electronic health records (EHRs) from Epic Systems and Cerner, enabling real-time clinical decision support.

The shift toward at-home POCT accelerated in 2026, with companies like Everlywell and LetsGetChecked offering FDA-authorized home collection kits for HbA1c, thyroid function, and cholesterol. Walgreens and CVS Health now operate over 1,200 in-store POCT kiosks offering rapid flu, strep, and COVID-19 testing, according to a 2025 report from JPMorgan Chase Healthcare.

Point-of-Care Testing vs. Traditional Lab Testing: Comparison Table

Name	Key Feature	Cost per Test	Best For	Verto Rating
Point-of-care testing	Results in 5–15 minutes at patient location	$15–$100	Emergency triage, chronic disease monitoring, infectious disease screening	8.5/10
Traditional lab testing	High throughput, multi-analyte panels, gold-standard accuracy	$5–$50	Comprehensive diagnostics, confirmatory testing, population screening	7.0/10
At-home test kits (mail-in)	Sample collection at home, lab analysis within 48 hours	$30–$150	Convenience, privacy, routine wellness monitoring	7.5/10
Wearable biosensors	Continuous monitoring via smartwatch or patch	$100–$500 (device)	Chronic condition management (glucose, cardiac)	8.0/10

Verto recommends point-of-care testing for acute care scenarios where time-to-result directly impacts treatment decisions, such as suspected myocardial infarction or sepsis. Traditional lab testing remains superior for complex panels requiring mass spectrometry or culture-based methods. At-home kits from Everlywell offer a middle ground for consumers managing chronic conditions like diabetes or thyroid disorders.

Who Should Use Point-of-Care Testing? (and Who Shouldn’t)

If you are a physician managing an emergency department with suspected stroke or heart attack patients, POCT works because it provides cardiac troponin and INR results within 15 minutes, enabling thrombolytic therapy decisions before irreversible damage occurs. If you are a patient with type 1 diabetes, continuous glucose monitors (CGMs) from Dexcom or Abbott’s FreeStyle Libre are a form of POCT that eliminates finger-stick calibration and provides real-time glucose trends.

If you are a patient requiring comprehensive metabolic panels or culture-based antibiotic susceptibility testing, POCT is not suitable because lateral flow assays and handheld analyzers cannot perform these complex analyses. Consider traditional lab testing instead. If you are a consumer seeking a full annual wellness workup, at-home mail-in kits from LetsGetChecked may provide broader panels but sacrifice the immediacy that defines true POCT.

Key Factors to Consider When Evaluating Point-of-Care Testing

Factor	What to Look For	Why It Matters
CLIA waiver status	FDA-cleared CLIA-waived designation	Enables use by non-laboratory personnel in any setting
Connectivity	Bluetooth, WiFi, or cellular data transmission	Automatic EHR integration reduces transcription errors
Sample type	Capillary blood, saliva, urine, or nasal swab	Determines patient comfort and collection ease
Test menu breadth	Single-analyte vs. multi-panel devices	Broader menus reduce device proliferation
Regulatory clearance	FDA 510(k) or De Novo authorization	Ensures analytical and clinical validity
Reagent shelf life	12–24 months at room temperature	Reduces waste and enables decentralized storage

When evaluating POCT for home use, prioritize devices with FDA authorization and clear patient instructions. For clinical settings, verify that the device integrates with your existing EHR system from Epic or Cerner to avoid manual data entry. Verto’s lifestyle category content includes reviews of at-home health monitoring devices and wellness test kits that align with POCT principles for North American consumers managing chronic conditions.